Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesSTU:USJ +3.78%67 Altman Z-Score is 4.36 as of Jul. 21, 2026, which is 55% below its 10-year median of 9.78. GuruFocus rates STU:USJ with a GF Score™ of 67/100 and a GF Value™ of €35.51 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,932 Consumer Packaged Goods companies, Usana Health Sciences ranks better than 70.13% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 4.34 is strong.
Usana Health Sciences has a Altman Z-Score of 4.36, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Usana Health Sciences's Altman Z-Score or its related term are showing as below:
STU:USJ'
s Altman Z-Score Range Over the Past 10 Years
Min: 3.94 Med: 9.78 Max: 15.79
Current: 4.34
During the past 13 years, Usana Health Sciences's highest Altman Z-Score was 15.79. The lowest was 3.94. And the median was 9.78.
Usana Health Sciences (STU:USJ) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Usana Health Sciences Altman Z-Score Related Terms
Usana Health Sciences Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:USJ vs NATR, ENHA, BYND: Altman Z-Score Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Altman Z-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Usana Health Sciences (STU:USJ) has a Altman Z-Score of 4.36 as of Jul. 21, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Usana Health Sciences and its competitors. This is 55% below median its historical median of 9.78. Over the past decade, Usana Health Sciences' Altman Z-Score has ranged from 3.94 to 15.79. According to the industry distribution chart, Usana Health Sciences ranks #577 out of 1932 companies in the Consumer Packaged Goods industry, placing it in the top 29.9%.
Is Usana Health Sciences' Altman Z-Score too high?
Usana Health Sciences' current Altman Z-Score of 4.36 is 55% below median its 10-year median of 9.78. Over the past 10 years, this metric has ranged from a low of 3.94 to a high of 15.79. The Consumer Packaged Goods industry median Altman Z-Score is 2.86. Usana Health Sciences' value of 4.36 is 52.7% above this industry median. Based on the distribution chart, Usana Health Sciences ranks #577 out of 1932 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Usana Health Sciences has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Altman Z-Score compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #577 out of 1932 companies for Altman Z-Score. This puts Usana Health Sciences in the upper half of its industry. The industry median Altman Z-Score is 2.86. Usana Health Sciences' value of 4.36 is 52.7% above this benchmark. Historically, Usana Health Sciences' own Altman Z-Score has ranged from 3.94 to 15.79 over the past decade. While the company's 10-year median is 9.78 vs. the industry median of 2.86, Usana Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Consumer Packaged Goods company?
The median Altman Z-Score among Consumer Packaged Goods companies is 2.86, based on 1,932 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Altman Z-Score of 4.36 is 52.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Altman Z-Score is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Altman Z-Score is 4.36, which is 55% below median its own 10-year median of 9.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (STU:USJ) is currently considered Possible Value Trap. The stock's GF Value™ is €35.51, compared to a current price of €19.20 — trading 45.9% below its estimated fair value. The current Altman Z-Score is 4.36, which is 55% below median its 10-year median of 9.78 and 52.7% above the Consumer Packaged Goods industry median of 2.86. Usana Health Sciences' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Usana Health Sciences (STU:USJ), the current Altman Z-Score is 4.36 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (STU:USJ) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of €19.20 is trading 45.9% below its estimated GF Value™ of €35.51.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for STU:USJ:
Altman Z-Score: 4.36 (55% below median its 10-year median of 9.78)
GF Value™: €35.51 vs. price of €19.20 (45.9% below fair value)
Industry Position: 52.7% above the Consumer Packaged Goods median (#577 of 1932)
No single metric tells the full story. See the STU:USJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
67GF Score
Get the complete analysis for STU:USJ
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:USJ has been successfully added to your 
